Vinorelbine and the topoisomerase 1 inhibitors: Current and potential roles in breast cancer chemotherapy Seamus O'ReillyM. John KennedyRoss C. Donehower New agents in breast cancer — minisymposium Pages: 1 - 17
Aromatase inhibitor development for treatment of breast cancer Shigeru MasamuraHerman AdlercreutzSteven J. Santner New agents in breast cancer — minisymposium Pages: 19 - 26
Current status of paclitaxel in the treatment of breast cancer Joyce A. O'ShaughnessyKenneth H. Cowan New agents in breast cancer — minisymposium Pages: 27 - 37
Current status of Taxotere® (docetaxel) as a new treatment in breast cancer P. FumoleauB. ChevallierM. Van Glabbeke New agents in breast cancer — minisymposium Pages: 39 - 46
Long term survival and the prognostic factors of advanced breast cancer patients treated with adreno-oophorectomy Yasuo NomuraHideya TashiroAkihiko Osaki Report Pages: 47 - 54
Age at menarche and breast cancer risk in nulliparous women P. H. M. PeetersA. L. M. VerbeekF. de Waard Report Pages: 55 - 61
Cyclical mastopathy and premenopausal breast cancer risk Pamela J. GoodwinGerrit DeBoerNorman F. Boyd Report Pages: 63 - 73
Early adult body weight, body mass index, and premenopausal bilateral breast cancer: data from a case-control study Giske UrsinAnnlia Paganini-HillRobert W. Haile Report Pages: 75 - 82
Evaluation of serum tumor markers in patients with advanced or recurrent breast cancer Hirotaka IwaseShunzo KobayashiAkira Masaoka Report Pages: 83 - 88
Detection of c-erbB-2 gene amplification in nipple discharge by means of polymerase chain reaction Kazuyoshi MotomuraHiroki KoyamaChihiro Azuma Brief communication Pages: 89 - 92